TAR-200 Monotherapy Promising for BCG-Unresponsive Bladder Cancer
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 21, 2025 -- For patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC), an intravesical gemcitabine-releasing system, TAR-200 monotherapy, is well tolerated with a high complete response (CR) rate, according to a study published online July 30 in the Journal of Clinical Oncology.
Siamak Daneshmand, M.D., from the University of Southern California Norris Comprehensive Cancer Center in Los Angeles, and colleagues conducted a phase 2b parallel cohort study involving patients with BCG-unresponsive carcinoma in situ with/without papillary disease who received TAR-200 monotherapy, TAR-200 plus cetrelimab, or cetrelimab monotherapy (cohorts [C] 2, 1, and 3, respectively). In addition, patients with BCG-unresponsive high-risk papillary disease-only NMIBC received TAR-200 monotherapy (C4).
Overall, 53, 85, 28, and 52 patients were treated in C1 to C4, respectively, as of data cutoff. The researchers found that the CR rate and median duration of response were 82.4 percent and 25.8 months, respectively, in C2. The six-, nine-, and 12-month disease-free survival rates were 85.3, 81.1, and 70.2 percent, respectively, in C4. CR rates were 67.9 and 46.4 percent in C1 and C3, respectively. In C2, C4, C1, and C3, rates of grade ≥3 treatment-related adverse events were 12.9, 13.5, 37.7, and 7.1 percent, respectively, and rates of serious treatment-related adverse events were 5.9, 5.8, 15.1, and 3.6 percent, respectively. There were no treatment-related deaths.
"The theory behind this study was that the longer the medicine sits inside the bladder, the more deeply it would penetrate the bladder and the more cancer it would destroy," Daneshmand said in a statement. "It appears that having the chemotherapy released slowly over weeks rather than in just a few hours is a much more effective approach."
Several authors disclosed ties to pharmaceutical companies, including Johnson & Johnson; the study was funded by Janssen Research & Development, a Johnson & Johnson company.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
Helping Others Linked to Higher Level of Cognitive Function
THURSDAY, Aug. 21, 2025 -- Helping others, both via formal volunteering and informal helping, is associated with higher levels of cognitive function and slower cognitive decline...
Work-Related Income Drops for Parents of Children Diagnosed With Type 1 Diabetes
THURSDAY, Aug. 21, 2025 -- Work-related income decreases sharply for mothers and fathers of children diagnosed with type 1 diabetes, with similar effects across sociodemographic...
Mothers of Children With Down Syndrome Report Need for Improved Screening Communications
THURSDAY, Aug. 21, 2025 -- A survey of mothers of children with Down syndrome (DS) reveals room for improvement to better support parental understanding of prenatal screening and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.